dorzolamide and Retinal-Detachment

To determine whether topical aqueous suppressants affect the duration of pure expansile intraocular gas in nonvitrectomized eyes.. A prospective randomized controlled trial was performed on nonvitrectomized patients undergoing retinal detachment repair with scleral buckle or pneumatic retinopexy using 0.3 mL of 100% perfluoropropane (C3F8) gas tamponade. Eyes were randomly assigned to receive topical dorzolamide 2% and timolol 0.5% twice daily postoperatively until gas dissolution or to observation.. Twenty-one patients met all inclusion and exclusion criteria. Twelve were randomized to the control group and nine to the dorzolamide-timolol group. In the dorzolamide-timolol group, mean intraocular pressure was 17.4 on postoperative Day 1 and 12.5 on postoperative Week 1 (P = 0.03). In the control group, mean intraocular pressure was 14.5 on postoperative Day 1 and 15.1 on postoperative Week 1 (P = 0.73). The mean duration of C3F8 was 37.8 days in the dorzolamide-timolol group and 40.4 days in the control group (P = 0.70).. Topical aqueous suppression does not seem to have a significant effect on the duration of pure expansile intraocular C3F8 in nonvitrectomized eyes after pneumatic retinopexy or scleral buckling.

Topics: Administration, Topical; Adult; Aged; Antihypertensive Agents; Aqueous Humor; Cryotherapy; Drug Combinations; Endotamponade; Fluorocarbons; Humans; Injections, Intraocular; Intraocular Pressure; Middle Aged; Ophthalmic Solutions; Prospective Studies; Retinal Detachment; Scleral Buckling; Sulfonamides; Thiophenes; Time Factors; Timolol; Vitrectomy

To determine whether a single topical aqueous suppressant applied immediately after pars plana vitrectomy with long-acting gas tamponade prevents intraocular pressure (IOP) elevation.. Fifty patients who met the inclusion criteria and underwent pars plana vitrectomy with long-acting gas tamponade were randomized to receive a combination of timolol maleate and dorzolamide hydrochloride, long-acting timolol alone, dorzolamide alone, or placebo at the conclusion of surgery. The IOP was checked by a portable, handheld tonometer (Tono-Pen) at the conclusion of surgery and at 5 hours, 1 day, and 1 week after surgery.. There were no significant differences in IOP among the groups at the conclusion of surgery. The IOP at 5 hours after surgery (27.0 vs 17.4 mm Hg; P<.001) and 1 day after surgery (26.1 vs 19.9 mm Hg; P =.01) showed a statistically significant difference between the placebo and timolol-dorzolamide groups. The timolol-dorzolamide group showed greater IOP control than either the timolol alone or the dorzolamide alone groups at 5 hours (P =.04 for both).. The use of a single topical aqueous suppressant (timolol-dorzolamide) given after pars plana vitrectomy with long-acting gas tamponade effectively prevents significant postoperative IOP elevation at 5 hours and 1 day after surgery.

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Drug Therapy, Combination; Female; Fluorocarbons; Humans; Intraocular Pressure; Male; Middle Aged; Postoperative Complications; Postoperative Period; Prospective Studies; Retinal Detachment; Retinal Perforations; Sulfonamides; Sulfur Hexafluoride; Thiophenes; Timolol; Vitrectomy

Wyburn-Mason syndrome is a rare phacomatosis characterized by unilateral arteriovenous malformations (AVMs) involving the brain, retina, and (rarely) the skin. The diagnosis is concluded with dilated fundus examination and markedly dilated tortuous vascular loops with arteriovenous communications on fluorescent angiography. We present a 14-year-old male patient with Wyburn-Mason syndrome who developed serous macular neuroretinal detachment, cystoid macular edema (CME), and consequent visual deterioration in the left eye. To the best of our knowledge, this is the first report of a patient with Wyburn-Mason syndrome who developed serous retinal detachment and CME.

Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Arteriovenous Fistula; Drug Therapy, Combination; Fluorescein Angiography; Glucocorticoids; Humans; Ketorolac Tromethamine; Macular Edema; Magnetic Resonance Imaging; Male; Neurocutaneous Syndromes; Prednisolone; Retinal Detachment; Subretinal Fluid; Sulfonamides; Thiophenes; Tomography, Optical Coherence; Triamcinolone Acetonide

Topics: Acute Disease; Antihypertensive Agents; Diclofenac; Drug Therapy, Combination; Female; Fluorescein Angiography; Glaucoma, Open-Angle; Humans; Middle Aged; Optic Disk; Optic Nerve Diseases; Retinal Detachment; Serum; Sulfonamides; Thiophenes; Timolol; Tomography, Optical Coherence; Vision Disorders; Visual Acuity